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Abstract
Background: New pre-clinical trials in AD mouse models may help to develop novel immunogen-
adjuvant configurations with the potential to avoid the adverse responses that occurred during the
clinical trials with AN-1792 vaccine formulation. Recently, we have pursued an alternative
immunization strategy that replaces QS21 the Th1 type adjuvant used in the AN-1792 clinical trial
with a molecular adjuvant, mannan that can promote a Th2-polarized immune response through
interactions with mannose-binding and CD35/CD21 receptors of the innate immune system.
Previously we established that immunization of wild-type mice with mannan-Aβ28 conjugate
promoted Th2-mediated humoral and cellular immune responses. In the current study, we tested
the efficacy of this vaccine configuration in amyloid precursor protein (APP) transgenic mice
(Tg2576).
Methods: Mannan was purified, activated and chemically conjugated to Aβ28 peptide. Humoral
immune responses induced by the immunization of mice with mannan-Aβ28 conjugate were
analyzed using a standard ELISA. Aβ42 and Aβ40 amyloid burden, cerebral amyloid angiopathy
(CAA), astrocytosis, and microgliosis in the brain of immunized and control mice were detected
using immunohistochemistry. Additionally, cored plaques and cerebral vascular microhemorrhages
in the brains of vaccinated mice were detected by standard histochemistry.
Results: Immunizations with low doses of mannan-Aβ28 induced potent and long-lasting anti-Aβ
humoral responses in Tg2576 mice. Even 11 months after the last injection, the immunized mice
were still producing low levels of anti-Aβ antibodies, predominantly of the IgG1 isotype, indicative
of a Th2 immune response. Vaccination with mannan-Aβ28 prevented Aβ plaque deposition, but
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unexpectedly increased the level of microhemorrhages in the brains of aged immunized mice
compared to two groups of control animals of the same age either injected with molecular adjuvant
fused with an irrelevant antigen, BSA (mannan-BSA) or non-immunized mice. Of note, mice
immunized with mannan-Aβ28 showed a trend toward elevated levels of CAA in the neocortex and
in the leptomeninges compared to that in mice of both control groups.
Conclusion: Mannan conjugated to Aβ28 provided sufficient adjuvant activity to induce potent
anti-Aβ antibodies in APP transgenic mice, which have been shown to be hyporesponsive to
immunization with Aβ self-antigen. However, in old Tg2576 mice there were increased levels of
cerebral microhemorrhages in mannan-Aβ28 immunized mice. This effect was likely unrelated to
the anti-mannan antibodies induced by the immunoconjugate, because control mice immunized
with mannan-BSA also induced antibodies specific to mannan, but did not have increased levels of
cerebral microhemorrhages compared with non-immunized mice. Whether these anti-mannan
antibodies increased the permeability of the blood brain barrier thus allowing elevated levels of
anti-Aβ antibodies entry into cerebral perivascular or brain parenchymal spaces and contributed to
the increased incidence of microhemorrhages remains to be investigated in the future studies.
Background
The neuropathological features of Alzheimer's disease
(AD) include neurofibrillary tangles (NFT), deposition of
amyloid-β (Aβ) in senile plaques, and neuronal loss in
affected brain regions [1]. The Aβ is cleaved from the amy-
loid precursor protein (APP) by the β- and γ-secretases [2-
4], and is believed to play an important role in the onset
and progression of AD [5,6]. Accordingly, many of the
strategies currently being proposed as therapies for AD are
aimed at reducing the level of Aβ in the brain, and/or pre-
venting the assembly of this peptide into pathological
forms. One potentially powerful strategy for reducing the
level of Aβ in the brain is immunotherapy, in which anti-
bodies specific for Aβ facilitate the clearance amyloid
deposits and a reduction in other forms Aβ in the brain
parenchyma. Both active and passive Aβ-immunotherapy
significantly decrease amyloid deposits, neuritic dystro-
phy and gliosis in the brain, as well as improve behav-
ioural measures in APP/Tg mice [7-12]. Based on these
and other studies in several animal models, the AN-1792
clinical trial was initiated in patients with mild-to-moder-
ate AD, however the trial was halted during the phase II
portion of the trial when approximately 6% of the AD
patients vaccinated with AN1792 developed meningoen-
cephalitis and in some cases CAA associated haemor-
rhages. The cause of the encephalitis in these patients has
not yet been determined, however speculation has
focused on autoreactive T-cells and the proinflammatory
Th1 type of adjuvant that was used in the clinical trial [13-
16]. Of note, there is only one unconfirmed report about
lymphocyte infiltration detected in the brains of wildtype
mice immunized with Aβ42 formulated in FCA/FIA fol-
lowed by injection with pertussis toxin [17]. In addition
to T cell infiltration into the brain parenchyma, another
participant in the clinical trial developed widespread cor-
tical hemorrhages [16]. Microhemorrhages in the cerebral
vasculature have also been observed in different strains of
very old (21–26 month-old) APP/Tg mice injected weekly
with high doses of anti-Aβ monoclonal antibodies, and
the sites of microhemorrhage have been co-localized with
cerebral vascular Aβ deposits [18-21]. Recently, it was
reported that active immunizations of APP/Tg mice with
fibrillar Aβ42 formulated in a strong conventional adju-
vant, Freund's complete adjuvant system (FCA), could
also increase microhemorrhages in the brains of vacci-
nated animals [22]. Collectively, these adverse events
emphasized the need for further refinement of vaccines
for AD in order to eliminate, or at least attenuate, the
potential adverse events initiated by infiltration of autore-
active T cells and peripheral macrophages, as well as
inflammation-induced cerebral vascular microhemor-
rhages.
Mannan and other polysaccharides are recognized by col-
lectins, such as, Mannose-Binding Lectin (MBL) [23-25],
as well as Mannose Binding Receptors (MBRs) expressed
on dendritic cells, some endothelial cells and macro-
phages [26-29]. After binding to mannan, MBL initiates
the complement pathway via an activation of the MASP-1
& MASP-2 proteases, and is antibody- and C1q-independ-
ent. Therefore, immunization of mice with Aβ peptide
sequences conjugated to mannan should induce comple-
ment activation and C3d opsonization on the Aβ. Moreo-
ver, MBL, which also has opsonic function like
complement C1q (homologue of MBL), binds to comple-
ment receptor type 1 (CR1/CD35) [30] and therefore
stimulates phagocytosis of the conjugated antigen.
Finally, T-cell dependent B-cell immune responses can be
activated not only by simultaneous triggering of BCR and
C' receptor type 2 (CD21), but also by simultaneous trig-
gering of BCR and C' receptor type 1 (CD35) [31,32].
Importantly, different groups have already demonstrated
enhancement of T-helper and B-cell immune responses
against several mannosylated-antigens, including pep-Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
Page 3 of 16
(page number not for citation purposes)
tide-antigens [33-35]. In addition to the direct activation
of C', Aβ-mannan conjugates will be recognized by MBRs
found on dendritic cells, some endothelial cells and mac-
rophages [26-28]. The macrophage mannose receptor
(MMR) and DEC-205 found on dendritic and some
endothelial cells bind multiple carbohydrates [36]. These
receptors significantly enhance phagocytosis of antigens
containing an appropriate carbohydrate, such as mannose
residues. In addition, the receptors can also increase anti-
gen presentation on macrophages and dendritic cells by
100- to 1,000-fold over antigens without carbohydrate
residues. Thus, besides activating complement, Aβ conju-
gated to mannan will also promote phagocytosis and anti-
gen presentation on macrophages and dendritic cells of
the immune system, providing an added benefit from the
conjugation of mannan to Aβ. Notably, under certain con-
ditions, mannosylated antigens induced strong Th2-type
anti-inflammatory responses (production of IL4/IL10
cytokines) with high levels of IgG1 antibodies
[33,34,37,38].
Previously, we generated mannan-Aβ28  conjugate and
demonstrated that immunization of wild-type mice with
this vaccine enhanced the production of IL4 (Th2-type)
cytokine followed by generation of antibodies specific to
the self-Aβ antigen [39]. Here for the first time we tested
the safety and efficacy of mannan-Aβ28  conjugate in
Tg2576 mouse model of AD. We demonstrated that, in
the absence of any conventional adjuvant, mannan-Aβ28
conjugate enhanced the production of Th2-type anti-Aβ
antibodies inhibiting Aβ plaque formation. However, the
mannan-peptide conjugate induced higher levels of
microhemorrhages compared to that in the brains of age-
matched control animals.
Methods
Preparation of mannan-Aβ28 immunoconjugate
Mannan (Saccharomyces cerevisiae, Sigma, MO) was puri-
fied by passage over a Q Sepharose FF column (GE
Healthcare) to remove residual nucleic acid. Mannan was
activated [40] and conjugated to Aβ28 peptide, as previ-
ously described[39]. In brief, a 10 mg/ml solution of man-
nan was activated by addition of the organic cyanylating
reagent 1-cyano-4-dimethylaminopyridinium tetrafluor-
oborate (CDAP) (25 μl/ml, 100 mg/ml in acetonitrile).
After 30 sec, 25 μl/ml of aqueous 0.2 M triethylamine
(TEA) was added. After another 2 min an equal volume of
0.5 M hexanediamine, pH 9, was added and the reaction
allowed to proceed overnight and then dialyzed against
water. The mannan concentration and the free amine con-
tent were determined as previously described [40]. The
amino-mannan was bromoacetylated using NHS bro-
moacetate, and desalted by dialysis. Aβ28 peptide (5.0 mg/
ml) with an N-terminal linker (n-CAGA) sequence syn-
thesized by (Multiple Peptide Systems, San Diego, CA)
was dissolved in 0.15 M HEPES, 2 mM EDTA, pH 7.3, and
the free thiol content determined using Ellman's reagent.
The peptide was combined with the bromoacetylated
mannan at a molar ratio of 30 thiols/100 kDa of carbohy-
drate under a stream of nitrogen. After an overnight reac-
tion, the solution was quenched by the addition of
mercaptoethanol concentrated with an Ultra 4 (10 kDa
cut-off) device (Millipore, MA), and free peptide removed
by gel filtration on a Sepharose 12 column (GE Health-
care, NJ), equilibrated with 0.1 M HEPES, pH 8. The void
volume peak was pooled. The peptide content was deter-
mined from the UV spectrum and its calculated extinction
coefficient. The final product contained 50 μM peptide at
a ratio of 5 moles of peptide per 100 kDa of mannan for-
mulated in PBS.
To generate a control mannan-antigen conjugate, mannan
was coupled with BSA via a thiol-ether linkage as
described for Aβ28 peptide except that the reaction was
quenched with ethanolamine before gel filtration on a
S300HR column (GE Healthcare, NJ). The peak tube from
the void volume was assayed by the Bradford method
using BioRad protein reagent, with BSA as the standard.
Finally, biotinylated mannan was prepared by reaction of
biotin-NHS with the amino-mannan, and un-reacted
biotin was removed by gel filtration.
Immunization of mice and detection of anti-Aβ and anti-
mannan antibodies
Based on our results with wild-type mice [39], we immu-
nized young 4–4.5 mo-old Tg2576 (APPsw) mice [Tg
(HuAPP695.K670N/M671L) 2576] [41,42] without pre-
existing AD-like pathology [43], (n = 8, 3 males, 5
females), six times biweekly with 10 μg/mouse of man-
nan-Aβ28 conjugate, subcutaneously (s.c.). Control mice
of the same age were either injected 6 times s.c. with man-
nan-BSA conjugate (n = 6, 3 males, 3 females), or
remained non-immunized (n = 5, 2 males, 3 females). We
collected sera on the 9th day after the last injection, or at
the end of the resting period (~11 months), and examined
the humoral immune responses by ELISA. Anti-Aβ anti-
bodies and their isotypes were detected in individual sera
as previously described [39,44-46]. Of note, concentra-
tions of anti-Aβ antibodies were calculated using a stand-
ard curve generated with 6E10 monoclonal antibody
(Signet, MA). Also, using a similar ELISA technique we
detected the titers of anti-mannan antibodies, although in
these experiments streptavidin pre-coated plate wells
(Express Biotech International, MD) were coated with 2
μg/ml biotinylated mannan as recommended by manu-
facturer before addition of immune or control sera.
Dot blot assay
Binding of anti-Aβ28 antibody to different forms of Aβ42
peptide was demonstrated as described [47]. Briefly, 1 μlJournal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
Page 4 of 16
(page number not for citation purposes)
of monomeric, oligomeric or fibrillar forms of Aβ42 (45
μM each) were applied to a nitrocellulose membrane.
After blocking and washing, the membranes were probed
with sera from mice immunized with mannan-BSA, man-
nan-Aβ28 (1 μg/ml), anti-Aβ 20.1 monoclonal (1 μg/ml)
antibody, or rabbit A11 polyclonal (1 μg/ml) antibody
previously described by [48]. The membranes were incu-
bated with appropriate HRP-conjugated anti-mouse
(1:2000) or anti-rabbit (1:2000) antibody (Santa Cruz
Biotechnology, CA). Blots were developed using Luminol
reagent (Santa Cruz Biotechnology, CA) and exposed to
Kodak X-Omat AR film.
Immunohistochemistry
After the termination of the study, we obtained the brains
of experimental and control mice (~18–18.5 months) and
analyzed the impact of active immunization with man-
nan-Aβ28 on neuropathological changes as we previously
described [47,49,50] Briefly, mice were halothane-anes-
thetized, perfused with PBS prior to removing the brains.
Brains were fixed (4% paraformaldehyde, 48 hrs), and
brain tissues were sectioned (40 μm thick) and stored at
4°C (PBS with 0.02% sodium azide). Staining of dupli-
cates of coronal sections of experimental and control
mouse brains, collected from 3 different planes of the
brain about 1 mm apart, with monoclonal anti-Aβ40 or
Aβ42 (Signet, MA) as we described [49].
The quantitative analysis of CAA was made as described
by [51]. Briefly, CAA score (based on frequency and sever-
ity) was quantified on the sections immunostained with
anti-Aβ40  throughout the neocortex. Six sections from
each brain in the groups of mice immunized with man-
nan-Aβ28, mannan-BSA or non-immunized animals were
analyzed. CAA frequency was calculated by counting the
total number of Aβ-positive vessels in the set of sampled
sections, while CAA severity was assessed using three
severity grades: grade 1, Aβ immunoreactivity confined
strictly to the vessel wall; grade 2, Aβ immunoreactivity in
and around vessel wall with focal infiltration of the amy-
loid in the neuropil; and grade 3, extensive infiltration of
amyloid into the neuropil with a complete amyloid coat
around the vessel. The mean for all vessels was taken as
CAA severity, and final CAA score was calculated by mul-
tiplying CAA frequency with CAA severity. All of the quan-
titations were done on both hemispheres by two
independent investigators and yielded similar results.
Binding of the pooled immune sera from the group of
mice immunized with mannan- Aβ28 to the 50 μm brain
section of formalin-fixed cortical tissue of a 75-year-old
woman with neuropathological and behavioural patterns
typical to severe AD, was done as we described previously
[45,47]. To demonstrate the specificity of binding of anti-
Aβ28 antibodies to the brain tissue we blocked antisera
from immune mice with the Aβ1–15 peptide at 5 μM con-
centration as described [47].
For detection of astrocytosis, we used cow glial fibrillary
acidic protein, GFAP (DAKO, Denmark). To detect micro-
gliosis, we used anti-mouse CD45 (LCA, Ly-5, Pharmin-
gen, CA). Anti-C1q and anti-C3b antibodies (eBioscience,
CA) were used to detect activation of complement as pre-
viously described [52]. Infiltration of T cells was analyzed
using anti-CD3-ε (Santa Cruz Biotechnology, CA) anti-
body. The tissues from all animals within a given experi-
mental group were processed in parallel. Hydrogen
peroxide-quenched and blocked sections were incubated
with primary antibody overnight at 4°C. Sections were
then washed and incubated with appropriate biotinylated
secondary antibodies against corresponding species. Col-
our developed via ABC and DAB (3,3'-diaminobenzidine)
substrate kits (Vector, CA). Images of the immunostaining
were captured using a Sony high-resolution CCD video
camera (XC-77), and quantification of staining was per-
formed using NIH image 1.59b5 software. For every ani-
mal, eighteen images (525 × 410 μm each) of the frontal
parietal region in the cortex area of 2 adjacent sections
were captured with 20× objective. Samples consisted of
nine images from the superficial layer and the remaining
nine from the deep layer. NIH imaging was used to ana-
lyze the area occupied by amyloid plaques, as well as
CD45- and GFAP-immunoreactivity. The threshold for
the detection of immunoreactivity was established and
then held constant throughout the image analysis. Addi-
tionally, we performed a visual inspection of hippocam-
pal and cortical regions of all stained sections in a blinded
fashion (observer had no knowledge of the treatment
group); a mean semi-quantitative score was independ-
ently determined for each slide by 2 observers.
Histochemistry
Determination of cored plaques was accessed using Thio-
flavin-S (ThS) according to a standard protocol from the
IBAD, UCI. Briefly, sections from immunized and control
animals were mounted on Vectabond-coated slides (Vec-
tor Labs, CA). Sections were then washed with Tris buffer
(0.1 M Tris buffered saline at pH 7.5) and stained with
0.5% ThS (Sigma, MO) in 50% ethanol for 10 min.
Finally, sections were washed in 50% ethanol, and twice
in Tris buffer, then dried and coverslipped with Vectash-
ield (Vector Labs, CA). ThS-positive plaques were counted
by visual inspection of cortical and hippocampal regions
of all stained sections in a blinded fashion; a mean semi-
quantitative score was independently determined for each
slide by 2 observers.
Determination of microhemorrhages was performed
using Prussian blue staining of ferric acid according to a
standard protocol from IBAD, UCI. Briefly, duplicates ofJournal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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coronal sections of experimental and control mouse
brains, 40 μm thick, collected from 3 different planes of
the brain (about 1 mm apart), were mounted on
Vectabond coated slides (Vector Labs, CA) and stained
with Prussian blue working solution, a mixture of freshly
made 5% Potassium hexacyanoferrate (II) trihydrate, and
5% hydrochloric acid (all from Sigma, MO). After 30 min
all sections were rinsed in water, counterstained with
Nuclear Fast Red (Sigma, MO), dehydrated and covered
using DPX (BDH Laboratory Supplies, England). The
hemorrhage profiles (hemosiderin stain) were counted by
two independent observers, and the average number of
Prussian blue-positive deposits was calculated for each
brain section.
For detection of co-localization of Aβ accumulation and
complement markers in vasculature we used combination
of two methods described above. First, sections were glass
mounted, peroxidase-quenched and stained with anti
C1q and C3b antibodies (eBioscience, CA) followed by
biotinylated secondary antibodies and streptavidin-Alexa
Fluor 555 (Thermo Fisher Scientific, IL). After that, ThS
staining was performed as described above. Confocal
images were collected on an Olympus IX70 inverted
microscope and a BioRad Radiance 2000 Laser Scanning
System using 70× objective for image analysis.
Statistical Analysis
To assess the differences in antibody titers, plaque areas,
glial immunoreactivity, frequency of microhemorrhages
and CAA in experimental mice versus the control groups,
a two-tailed Students's t-tests were performed using Graph
Pad Prism 3.03 software.
Results
Mannan-Aβ28 immunoconjugate induced potent anti-Aβ 
antibody responses in the Tg2576 mouse model of AD
Previously, we have demonstrated that 10 μg of human
mannan-Aβ28 peptide conjugate enhanced Th2 type anti-
Aβ antibody production in wild-type mice[39]. In the cur-
rent study we first analyzed the immunogenicity of man-
nan-Aβ28 immunoconjugate in the Tg2576 mouse model
of AD in which Aβ28 is a self-antigen. After six biweekly
immunizations with the same low dose (10 μg) of man-
nan-Aβ28  antigen, 5 out of 8 Tg2576 mice generated
robust anti-Aβ antibody production, whereas the remain-
ing mice expressed less than 5 μg/ml of antibodies (Figure
1A). Average anti-Aβ antibody concentrations were 10.4
μg/ml, equal to titers of ≥ 1:10,000. The humoral immune
response generated by the mannan-Aβ28 immunogen was
long lasting since the anti-Aβ antibody concentration
remained readily detectable (0.8 μg/ml or approximately
a titer of ≥ 1:800) in vaccinated animals that were held
free of immunizations for 11 months (Figure 1A). Anti-
body isotyping can be used as an indirect measure of the
contribution of Th1 (IgG2a) and Th2 (IgG1) cytokines to
the humoral response[53]. Additionally, the subclass of
anti-Aβ antibodies may correlate with their therapeutic
potential[11,54]. Thus, we measured the production of
IgG1, IgG2ab, IgG2b, and IgM anti-Aβ antibodies in the
sera of vaccinated Tg2576 mice, demonstrating that man-
nan-Aβ28  induced predominantly IgG1, although two
mice also produced significant amount of IgM antibody
(Figure 1B). Interestingly, the isotypic profile of anti-Aβ
antibodies was similar at 9 days and 11 months after the
last boost (Figure 1B), and the ratios of IgG1 to IgG2ab
antibody in these mice were 8.2 and 5.25, respectively.
Thus, immunization with the Aβ28  immunoconjugate
induced long-lasting therapeutically potent anti-Aβ anti-
bodies in Tg2576 mice, and the humoral immune
response was Th2-polarized, similar to the observations
after the conjugation of mannan with other peptide
immunogens [33,37,38] or immunizations of wildtype
mice with mannan-Aβ28[39].
Mannan was previously shown to be a weak T-independ-
ent antigen, however because the mannan was conjugated
to a peptide (Aβ) or a protein (BSA), both of which con-
tain T helper cell epitopes that can be used to promote the
production of anti-mannan antibodies, we analyzed the
antibody response to mannan induced by immunizations
with mannan-Aβ28  or mannan-BSA conjugates. As we
expected, both groups of mice induced only low titers of
anti-mannan antibodies at day 9 after the last boost (Fig-
ure 1C). The anti-mannan antibodies were of the IgG and
IgM isotypes in mice immunized with mannan-Aβ28 and
predominantly of IgG isotypes in mice immunized with
mannan-BSA (Figure 1D). It was not surprising that both
immunoconjugates induced IgG anti-mannan antibodies
because Aβ28 [44] and BSA possess T helper epitope/s that
make mannan-peptide/protein conjugate a T-dependent
antigen.
In the light of recent data that oligomeric forms of Aβ42
peptide are the most toxic forms, we analyzed the binding
ability of immune and control sera to Aβ monomers, oli-
gomers and fibrils by a dot blot assay. Sera from mannan-
Aβ28 immunized, but not from mannan-BSA immunized
mice, bound to all forms of Aβ42, although binding was
better to the monomeric and oligomeric forms than to
fibrillar Aβ42  (Figure 1E). We also demonstrated that
immune sera bound to Aβ plaques in the brain tissue
from an AD clinical case. This binding was specific since
pre-incubation of sera with the Aβ1–15 peptide resulted in
its complete inhibition (Figure 1F).
Immunization with mannan-Aβ28 inhibits AD-like amyloid 
pathology in the brain
Next, we analyzed the extent of AD-like pathology in
brains of vaccinated Tg2576 mice (18–18.5 months old).Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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As controls, we used Tg2576 mice of the same age injected
with mannan-BSA, or non-immunized group of animals.
Image analysis of anti-Aβ40  and anti-Aβ42  antibody-
stained parietal cortical sections demonstrated a signifi-
cant reduction of amyloid plaques in brains of mice vacci-
nated with mannan-Aβ28 compared with similar brain
staining of non-immunized mice (Figure 2) or animals
injected with mannan-BSA (data not shown). While stain-
ing with anti-Aβ40 and anti-Aβ42 antibodies detected both
cored and diffuse plaques, ThS binds only to cored amy-
loid deposits. Therefore, we compared image analyses
with ThS staining of parietal cortical brain sections from
Mannan-Aβ28 immunoconjugate induces potent levels of anti-Aβ and low levels of anti-mannan antibodies in Tg2576 mice Figure 1
Mannan-Aβ28 immunoconjugate induces potent levels of anti-Aβ and low levels of anti-mannan antibodies in 
Tg2576 mice. A. Vaccinated mice 7–7.5 months of age produced on average 10.4 μg/ml of anti-Aβ antibodies (approximate 
titers ≥ 1:10,000) after 6 immunizations. At termination, when mice reached 18–18.5 months of age they still produced low 
levels of anti-Aβ antibodies (0.8 μg/ml or approximate titers ≥ 1:800). Noteworthy, mice immunized with mannan-BSA did not 
produce detectable levels of anti-Aβ antibodies (data not shown). B. Mannan-Aβ28 induced primarily IgG1 isotype antibodies, 
indicative of a Th2 type humoral immune response before resting period (sera were collected on 9th day after the last boost) 
and after resting period (sera were collected after 11 months). One vaccinated mouse also induced high level of IgM anti-Aβ 
antibodies. C. After 6 injections vaccinated mice produced low titers of anti-mannan antibodies. Of note, the titers of anti-man-
nan antibodies dropped dramatically during the intervening 11 months following the final injection (data not shown). (D). Man-
nan-Aβ28 as well as mannan-BSA induced only low levels of anti-mannan antibodies predominantly of IgG and IgM isotypes in 
mice immunized with mannan-Aβ28, and IgG isotypes for mice immunized with mannan-BSA. E. Anti-Aβ28 antibodies bind to all 
species of Aβ42 peptide. One μl of Aβ42 fibrils, oligomers and monomers (45 μM each) were applied in duplicate to a nitrocel-
lulose membrane and probed with sera from mannan-BSA immunized mice (control), sera from mice immunized with mannan-
Aβ28, anti-Aβ 20.1 monoclonal antibody and rabbit A11 antibody shown to bind oligomeric forms of Aβ42. (F). Binding of 
immune mannan-Aβ28 sera to the AD brain section. Binding of antisera was blocked by Aβ1–15 peptide. Original magnification, 
20×, scale bar = 100 μm.Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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vaccinated and control Tg2576 mice. We found that mice
actively immunized 11 months earlier with the mannan-
Aβ28 conjugate had significantly reduced depositions of
cored amyloid plaques (Figure 2D). A similar reduction in
Aβ40 and Aβ42 amyloid burden, as well as cored plaques
was observed in the hippocampus of vaccinated mice
compared with control non-immunized animals (Figure
2A). Of note, we observed no changes in Aβ depositions
by immunohistochemistry or histochemistry in the brains
of mice immunized 6 times with mannan-BSA compared
to non-immunized control (data not shown). Collec-
tively, these results demonstrate that the mannan-Aβ28
immunogen induced therapeutically potent anti-Aβ anti-
bodies, predominantly of the IgG1 isotype, that effectively
reduced the deposition AD-like plaque pathology in 18–
18.5 months old Tg2576 mice.
Immunizations with mannan-Aβ28 reduced glial activation 
in brains of Tg2576 mice
It was previously reported that following active and pas-
sive Aβ-immunotherapy, microglia activation in brains of
aged APP/Tg mice was attenuated [55-59]. In the current
study, we investigated the relationship between a reduc-
tion in fibrillar amyloid deposition and the state of micro-
glial activation in the brains of Tg2576 mice. After eleven
months mannan-Aβ28 vaccination there was significantly
less microglia activation as detected both in the frontal
cortex and in the hippocampus using anti-CD45 antibody
Vaccination with mannan-Aβ28 attenuates amyloid deposition in the cortical and hippocampal regions of brains Figure 2
Vaccination with mannan-Aβ28 attenuates amyloid deposition in the cortical and hippocampal regions of 
brains. A. Representative images of hippocampal region from non-immunized controls and mice immunized with mannan-Aβ28 
showing reduction of Aβ42 and Aβ40 amyloid burden or cored amyloid plaques. Aβ deposits were stained with anti-Aβ42, anti-
Aβ40 antibodies, and with ThS. Original magnifications, 5× for anti-Aβ42/40 staining and 4× for ThS (scale bars = 200 μm). B, C, 
D. Image analysis of Aβ42 (B), Aβ40 (C) staining, and number of ThS-positive cored plaques (D) in cortex of 18–18.5 mo old 
Tg2576 non-immunized mice and mice immunized with mannan-Aβ28. Vaccinated mice showed significant reduction in Aβ42 (P 
= 0.0075), Aβ40 (P = 0.0103) burden, and in number of ThS-positive cored plaques (P = 0.0019) compared to that in non-immu-
nized control group. Bars represent mean ± SE from n = 5 in the group of non-immunized mice, and n = 8 in the group of mice 
immunized with mannan-Aβ28.Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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immunostaining and image analysis (Figure 3A, C). In
fact, in the hippocampus areas of vaccinated mice we
detected only a few cells weakly stained for CD45, while
similar brain areas of the age-matched non-immunized
Tg2576 mice (Figure 3C) or mannan-BSA (data not
shown) were stained intensively for CD45.
It was previously shown that Aβ immunotherapy may
reduce neuritic dystrophy and astrogliosis, along with
reversing memory deficits in mouse models of AD
[11,60,61]. To determine the role of vaccination with
mannan-Aβ28 in the reduction of astrocytosis, we stained
brains of vaccinated and non-immunized control mice
with anti-GFAP antibody. Image analyses of parietal corti-
cal tissues demonstrated that brains of vaccinated mice
were stained less robustly than those of control animals.
Although, there was a trend toward less stimulation of
astrogliosis, it did not reach significance in the cortex (Fig-
ure 3B), a similar trend was also observed in the hippoc-
ampus region of brains from vaccinated mice (Figure 3D).
Vaccination with mannan-Aβ28 immunoconjugate induced 
microhemorrhage
Previous studies have shown that passive immunotherapy
with high doses of anti-Aβ antibodies may induce micro-
hemorrhage in aged APP/Tg mice [18,21]. More recently,
it was reported that multiple (10 times) immunizations of
APP+PS1 mice with high doses of fibrillar Aβ42 formu-
lated in conventional adjuvant (FCA/FIA) could also
increase microhemorrhage in 20 months old mice [22].
Interestingly, in PDAPP mice passive vaccination with
anti-Aβ antibodies cleared vascular amyloid, but high
doses of antibodies induced microhemorrhages that are
limited to focal perivascular sites [62]. Here, we analyzed
microhemorrhage in 18–18.5 months-old Tg2576 mice,
vaccinated with low doses of mannan-Aβ28, for 11
months prior to sacrifice, by hemosiderin staining with
Effects of vaccination with mannan-Aβ28 on microglial and astrocyte activation in Tg2576 mice Figure 3
Effects of vaccination with mannan-Aβ28 on microglial and astrocyte activation in Tg2576 mice. Image analysis of 
cortical sections performed after staining with anti-CD45 (A) and anti-GFAP (B) antibodies of brain sections from non-immu-
nized controls and mice immunized with mannan-Aβ28. Significantly less microglial activation (P = 0.0003) and lower level of 
astrocytosis (P = 0.3263) were detected after immunization with mannan-Aβ28 compared to non-immunized control mice. 
Representative pictures of staining with anti-CD45 (C) and anti-GFAP (D) antibodies showing a decrease in immunoreactivity 
in hippocampal areas of brain sections of mice immunized with mannan-Aβ28 versus control non-immunized mice. Original 
magnifications: 5×, scale bar = 200 μm.Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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Prussian blue. Numbers of positive profiles per section of
the brains of mannan-Aβ28 vaccinated animals were com-
pared with that in the brains of control age-matched ani-
mals immunized with mannan-BSA, or non-immunized
mice. We observed low numbers of microhemorrhage in
both non-immunized and mannan-BSA injected control
aged mice. In contrast, following vaccination with man-
nan-Aβ28, we detected significantly (P  < 0.001) higher
numbers of microhemorrhage (Figure 4A). Additionally,
we observed larger microhemorrhage in mice vaccinated
with mannan-Aβ28 (Figure 4B, C, D), than in mannan-
BSA (Figure 4E, F), or non-immunized control animals
The incidence and severity of vascular microhemorrhages increased following mannan-Aβ28 immunizations Figure 4
The incidence and severity of vascular microhemorrhages increased following mannan-Aβ28 immunizations. A. 
Quantification of Prussian blue staining based on the total number of positive profiles per section for mice injected with man-
nan-Aβ28, mannan-BSA, or non-immunized group. The levels of microhemorrhages were increased in vaccinated Tg2576 mice 
(n = 8) to 6.81 ± 2.6 compared to that of 2.31 ± 0.84 in mice immunized with mannan-BSA (n = 6), and 2.07 ± 0.58 in non-
immunized animals (n = 5). *** Indicates P < 0.001. B-G. Examples of microhemorrhage severity in the brain sections of mice 
injected with mannan-Aβ28 (B, C, D), mannan-BSA (E, F), or non-immunized animals (G). B. A focal microhemorrhage (arrow) 
at the cortical-subcortical junction, below the gray-white matter border, lateral to hippocampus. C. Representative images of 
the Prussian blue-positive blood vessels (arrows) most prominent in the meningeal, superficial parenchymal and cortical ves-
sels. D. A focal hemorrhage in the area of anterior commissure. E. A single microhemorrhage (arrow) in the white matter 
region. F. Microhemorrhage-free cortical and leptomeningeal areas. G. Two microhemorrhages (arrows) in the cortical and 
white matter regions. Original magnification, 10×, scale bar = 100 μm.Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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(Figure 4G). Previously, it was demonstrated that passive
Aβ-immunizations resulted in reduction of amyloid dep-
osition, but also increased incidence of microhemorrhage
associated with increased CAA in humans [14] and APP/
Tg mice [20]. Thus, we undertook a semi-quantitative
analysis of the CAA in the cortical brain sections of mice
injected with mannan-Aβ28, mannan-BSA, or non-immu-
nized animals. CAA score was calculated based on the fre-
quency and severity of the Aβ immunoreactivity confined
strictly to the vessel wall, around vessel wall with focal
infiltration of the amyloid in the neuropil, or extensively
infiltrated into the neuropil with a complete amyloid coat
around the vessel as it is shown in Figure 5A, B, C. Using
this approach we calculated CAA in neocortical areas of
experimental and control animals and demonstrated that
the CAA score was almost equal in mice vaccinated with
mannan-Aβ28, mannan-BSA or non-immunized control
(P > 0.05, Figure 5D). Of note, we did not quantitate CAA
in the meninges in this study, because the above men-
tioned standard Aβ burden measurements made in the
parenchyma and normalized to brain region were not
applicable to the meningeal location of vascular Aβ
deposits.
Since the activation of the complement cascade by anti-
body-Aβ immune complexes at sites of cerebral amyloid
angiopathy (CAA) may be one possible cause of microhe-
morrhage, it was of interest to analyze the opsonization of
sites of microhemorrhage with C1q and C3 proteolytic
fragments, C3b, complement components in mice immu-
nized with mannan-Aβ28. We detected the accumulation
of these complement proteins in the cerebral vasculature
Semi-quantitative analysis of CAA in the neocortex areas of animals immunized with mannan-Aβ28, mannan-BSA, or non-immu- nized mice Figure 5
Semi-quantitative analysis of CAA in the neocortex areas of animals immunized with mannan-Aβ28, mannan-
BSA, or non-immunized mice. A, B, C. Examples of CAA severity grades: grade 1, Aβ immunoreactivity confined strictly 
to the vessel wall (A); grade 2, Aβ immunoreactivity in and around vessel wall with focal infiltration of the amyloid in the 
neuropil (B); grade 3, extensive infiltration of amyloid into the neuropil with a complete amyloid coat around the vessel (C). 
Original magnification 20×, scale bar = 50 μm. D. The CAA score detected in the neocortex of mice vaccinated with mannan-
Aβ28, was similar to that detected in neocortex of animals injected with mannan-BSA or non-immunized mice (P > 0.05). Bars 
represent mean ± SE from n = 5 in the group of non-immunized mice, n = 6 in the group of mannan-BSA immunized group, and 
n = 8 in the group of mice immunized with mannan-Aβ28.Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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of immunized, but not control mice immunized with
mannan-BSA (Figure 6A). In the meningeal vessels, in the
group of mannan-Aβ28 immunized animals we have dem-
onstrated partially cleared ThS-stained vascular fibrillar
Aβ deposits abundantly decorated with C1q component
of complement, while only trace amount of C1q was co-
localized with compact Aβ load in the meninges of man-
nan-BSA immunized group, and practically none of the
C1q was detected in the Aβ-laden meninges of non-
immunized animals (Figure 6B). The similar co-localiza-
tion pattern was shown for C3b component of comple-
ment (data not shown).
Discussion
Anti-Aβ immunotherapy is one strategy for the inhibi-
tion/reduction of soluble and insoluble amyloid-β depos-
its that likely play a causal role in the onset and
progression of AD [5,6]. Several pre-clinical studies with
mouse models of AD have demonstrated the ability of Aβ
vaccination to prevent amyloid deposition in the brain.
Thus, active immunization with Aβ [7,63], as well as pas-
sive immunization intraperitoneally [11], or direct to the
brain application of anti-Aβ antibodies[64], resulted in
reduction of the amyloid burden in the brain. Impor-
tantly, active immunizations prevented cognitive decline
[8,9], and passive immunizations were shown to reverse
the memory loss in aged Tg2576 mice [65]. While these
and other studies did not report any adverse events in AD
mouse models immunized with fibrillar Aβ42, data from
the AN-1792 vaccine trial suggest that the adverse reac-
tions to Aβ42-immunotherapy were not due to the
humoral antibody response, but rather to the cell-medi-
ated autoimmune response, possibly exacerbated by the
reformulation of adjuvant, QS21 supplemented with
polysorbate-80, which induced a Th1 type immune
response in patients that received the AN1792 vaccine
[13-16,63,66-69]. Thus, the goal of this pre-clinical study
was to employ a molecular adjuvant, mannan, that
induces a Th2-type humoral immune response specific to
Aβ peptide, and test the efficacy of vaccination on AD-like
pathology in aged Tg2576 mice.
Previously, mannan was shown to enhance both humoral
and cellular immunity against various immunogens con-
Immunostaining of neocortex for C1q and C3b components of complement, and concomitant staining of meninges for C1q and  ThS Figure 6
Immunostaining of neocortex for C1q and C3b components of complement, and concomitant staining of 
meninges for C1q and ThS. A. Representative images of cortex areas of coronal brain sections of mice immunized with 
mannan-Aβ28 or mannan-BSA, immunostained with antibodies specific for C1q and C3b components of complement. Original 
magnification, 20×, scale bar = 50 μm. B. Representative images of colocalization of vascular fibrillar Aβ detected with ThS 
(green) with C1q component of complement (red) in the meninges of coronal brain sections of mice immunized with mannan-
Aβ28, mannan-BSA or non-immunized animals. Original magnification, 70×.Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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jugated to mannan. Multiple mechanisms likely contrib-
ute to the adjuvant properties of mannan conjugates,
including activation of complement, enhancing uptake
and presentation of the conjugated antigen, as well as by
providing a stronger signal to antigen-specific B cells by
simultaneous triggering of B-cell receptors and CD21/
CD35 molecules [26-28,31-35,70-75]. Notably, under
certain conditions mannan was shown to induce predom-
inantly Th2 polarized anti-inflammatory immune
responses to a conjugated non-self peptides
[33,34,37,38], a response which would presumably be
beneficial to an anti-Aβ vaccine. We previously reported
that Aβ42 possesses B and T cell antigenic epitopes, both of
which are contained within the Aβ28 peptide in mice [44].
In addition, our previous studies in wild-type mice using
mannan conjugated to Aβ28 peptide was able to induce
potent and highly polarized Th2 phenotype anti-Aβ anti-
body responses [39]. In the current study, we immunized
anti-Aβ hyporesponsive Tg2576 mice with mannan-Aβ28
conjugate prior to the onset of amyloid plaque pathology
in the brains of Tg2576 mice [43,76]. Mice were immu-
nized six times with low doses (10 μg per mouse) of man-
nan-Aβ28 conjugate and the titer of anti-Aβ antibodies
were assessed by ELISA. The antibodies induced by the
mannan-Aβ28 conjugate were predominantly of the IgG1
isotype and elevated titers were maintained for 11 months
without further immunizations (Figure 1A, B). Thus, we
demonstrated that our mannan-Aβ28 immunoconjugate
induced long-lasting and Th2-polarized anti-Aβ humoral
immune responses in Tg2576 mice in the absence of a
conventional adjuvant, such as alum or CFA. The humoral
immune response induced by mannan-Aβ28 was similar
to that reported after multiple injections of 5 to 10 times
higher doses of fibrillar Aβ42 formulated in strong Th1 or
Th2 conventional adjuvants [7,8,44,77-79].
We examined the effect of mannan-Aβ28 vaccination on
the neuropathology in 18–18.5 months old mice, and
showed a significant reduction in both the Aβ40 and Aβ42
burden, as well as in the number of ThS positive cored
plaques in the parietal cortical and hippocampal regions
(Figure 2) of the brains from mice immunized 11 months
earlier. Of note, previously we demonstrated that Aβ load
was significantly reduced in the brains of Tg2576 mice
with a high concentration of serum anti-Aβ1–11 antibody
(>50 μg/ml), whereas moderate concentration (5–50 μg/
ml) of this antibody resulted in a trend toward a reduction
in Aβ deposits, however it did not reach significance [49].
In the current study antibody specific to Aβ28 even at a
moderate concentration (Figure 1A) significantly reduced
both Aβ40 and Aβ42 deposits. This difference in potency of
anti-Aβ antibody may be due not only to the different
antigen configurations, but also to the starting point of
immunization. More specifically, immunization with
mannan-Aβ28 was started in mice without pre-existing
pathology (preventive vaccination strategy), whereas in
previous study [49] immunization was initiated in mice
with established AD-like pathology (therapeutic vaccina-
tion strategy). Of note, we did not detect any CD3-posi-
tive T cells in the brains of mice immunized with mannan-
Aβ28 (data not shown). Thus, inhibiting Aβ deposition in
immunized Tg2576 mice was not associated with any
adverse events, except for the increase in microhemor-
rhages.
The first two case reports from the AN-1792 clinical trial
both reported meningoencephalitis with lymphocyte
infiltration in the brain [15,16]. Additionally, the third
case report demonstrated increased CAA without clinical
presentation of meningoencephalitis, however there was
noticeable perivascular T cell infiltration [14]. It is worth
mentioning, that a high degree of CAA typically indicates
that hemorrhages are present in the brain [80,81]. How-
ever, only the case report from an AD patient from the Bar-
celona cohort of the AN-1792 trial found fully developed
hemorrhages [16]. The data on anti-Aβ immunotherapy
in experimental mouse models of AD are somewhat dif-
ferent. Normally, rodents do not develop Aβ-CAA, except
several APP transgenic mice models, including aged
Tg2576 mice developing vascular amyloid in addition to
the significant parenchymal amyloid [82,83]. Impor-
tantly, several studies with aged APP/Tg mice reported cer-
ebral vascular microhemorrhages after passive transfer of
high doses of anti-Aβ antibodies [18,20,84]. Additionally,
it was shown that 3D6 antibody specific to N-terminal
region of amyloid, but not antibody against Aβ16–23 (266)
prevented or cleared vascular Aβ in a dose-dependent
manner, but high concentration of this antibody was asso-
ciated with microhemorrhages in focal perivascular sites
[62]. Recently, it was reported that active immunizations
with a high dose of fibrillar Aβ42  plus CFA/IFA also
increased microhemorrhage in aged APP/Tg mice [22].
However, only one study reported meningoencephalitis
in an APP/Tg mouse model passively immunized with
repeated injections of high doses of monoclonal anti-Aβ
antibodies (1 mg within 16 days). Although only 1 out of
21 experimental mice were affected, the authors nonethe-
less suggested that an inflammatory mechanism might be
triggered by antibody binding to cerebral CAA, which in
turn may enhance activation of autoreactive T cells, or
lead to local disruption of the BBB [85]. Accordingly, in
the current study we sought to investigate whether immu-
nization with a mannan-Aβ28  conjugate might induce
infiltration of T cells or increase the incidence of microhe-
morrhages, and CAA. While an examination of the brains
did not reveal meningoencephalitis induced by the pres-
ence of T lymphocytes (data not shown), we observed an
increased incidence and the severity of microhemorrhages
in Tg2576 mice vaccinated with mannan-Aβ28 (Figure 4).
CAA-associated microhemorrhage in aged APP/Tg mice,Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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was ameliorated with deglycosylation of antibodies used
for passive immunization [21], implicating the potential
harmful effect of mannan as the trigger of adverse vascular
events. Thus, we attempted to demonstrate CAA-associ-
ated microhemorrhages in vaccinated animals with anti-
Aβ antibodies. We have started with examination the
meningeal and cortical vascular Aβ burden, because simi-
lar to human vascular Aβ, in mice it is first detectable
within leptomeninges, followed mostly by cortical, hip-
pocampal and thalamic areas [86,87]. By 12 months of
age, Aβ deposits in Tg2576 mice are present in the walls of
leptomeningeal and cortical blood vessels, and at 15
months, the percentage load of Aβ-CAA in these areas is
about 1.46% [88]. As mice in our study approached 18
mo of age, the CAA score in neocortex appeared to be sim-
ilar in all groups of experimental and control mice (Figure
5D). Of note, in this study we had not quantified the dif-
ference in the leptomeninges of experimental animals pre-
cisely, due to non-applicability of the standard percentage
area measurements of Aβ made in parenchyma and nor-
malized to brain region to the measurements of the
meningeal location of vascular Aβ deposits.
Although the perivascular macrophages express high lev-
els of mannose receptors [29], it is unlikely that mannan
fused with Aβ28 could cross the BBB and activate these
cells. Of note, infiltration of perivascular macrophages
has been detected predominantly in gray matter, with the
corpus callosum having very few cells, although substan-
tial microhemorrhages in our study were detected among
other areas, both in gray matter and in corpus callosum.
In addition, immunization with mannan-BSA did not ele-
vate the level of hemorrhages compared with low profiles
observed in non-immunized mice (Figure 4).
Notably, titers of the anti-mannan antibodies in mannan-
BSA group were higher than that in mice vaccinated with
mannan-Aβ28 (Figure 1C). Although these data indicate
that anti-mannan antibodies did not contribute directly to
the adverse cerebral vascular events, it is possible that they
may contribute to an increase in BBB permeability,
thereby increasing access of anti-Aβ antibody to perivascu-
lar and parenchymal spaces in mice vaccinated with man-
nan-Aβ28. Importantly, we previously demonstrated that
mannan-Aβ28 or Aβ28 alone did not induce microhemor-
rhage in the brains of wild-type mice [39].
Thus, we hypothesize that a potential cause for the inci-
dences of microhemorrhage detected in Tg2576 mice
immunized with mannan-Aβ28 may be anti-Aβ antibody
binding to Aβ in cerebral vasculature. If so, one potential
culprit in the microhemorrhage may be the activation of
the complement cascade by antibody-Aβ immune com-
plexes at sites of CAA [89,90]. Our data demonstrating
that C1q and C3b are found in the cortical brain sections
of mice immunized with mannan-Aβ28, but not control
animals (Figure 6A) indicate that binding of antibody-Aβ
to Aβ deposits in the cerebral vasculature may in fact
induce microhemorrhages. Of note, we demonstrated that
the level of decoration of ThS-stained vascular fibrillar Aβ
with complement components C1q (Figure 6B) and C3b
(data not shown) was highest in the meninges of mice
immunized with mannan-Aβ28. In this group, β-amyloid
deposits had altered morphology suggestive of ongoing
clearance, and were heavily decorated with C1q compo-
nent of complement. On the contrary, very small or prac-
tically absent C1q profiles were co-localized with
substantial and unaltered Aβ load of the meninges of BSA-
mannan-immunized or non-immunized groups, respec-
tively (Figure 6B). Importantly, recently it was shown that
microhemorrhages in PDAPP mice passively immunized
with the 3D6 antibody, being dose-responsive, co-local-
ized with the vascular amyloid accumulations having
altered Aβ morphology [62].
It is noteworthy that the microhemorrhages triggered by
anti-Aβ antibodies may play an important role in reduc-
tion of AD-like pathology, which we observed in aged
Tg2576 mice vaccinated with mannan-Aβ28. This seems
plausible, since only low concentrations of free anti-Aβ
antibodies were detected in the sera of vaccinated mice
after 11 months without further boosting with the man-
nan-Aβ28, and mannan-BSA did not induce microhemor-
rhages. Although we observed less total glial activation in
the brains of mice vaccinated with mannan-Aβ28than in
the brains of control animals (Figure 3), it is possible that
areas affected by microhemorrhages may have higher
CD45 and GFAP immunoreactivity. Future studies of the
underlying mechanisms responsible for the antibody-
induced microhemorrhages in mice may be useful for
avoiding these potentially adverse events in AD patients
receiving anti-Aβ immunotherapy.
Conclusion
Our novel vaccine candidate based on Aβ28 conjugated to
mannan, as the molecular adjuvant, induced production
of anti-Aβ antibodies in Tg2576 mice, which have been
shown to be hyporesponsive to immunization with Aβ
self antigen, in the absence of conventional adjuvant. As
expected, the mannan-Aβ28 conjugate induced the genera-
tion of Th2-type anti-Aβ antibodies, which significantly
attenuated amyloid deposition in old Tg2576 mice. How-
ever, there were increased levels of cerebral microhemor-
rhage in mannan-Aβ28 immunized mice, which did not
appear to be due to the anti-mannan antibody response
induced by the immunoconjugate, because mice immu-
nized with mannan-BSA generated higher titers of anti-
mannan antibodies than mice immunized with mannan-
Aβ28 and they did not show elevated levels of microhem-
orrhage. Whether the anti-mannan antibodies increasedJournal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42
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the permeability of the BBB thus allowing elevated levels
of anti-Aβ antibodies entry into cerebral perivascular and
parenchymal spaces contributed to the increased inci-
dence of microhemorrhages remains to be investigated in
future studies.
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